Implications of KRAS mutations in acquired resistance to treatment in NSCLC.
Implications of KRAS mutations in acquired resistance to treatment in NSCLC.
复制标题
DOI：
10.18632/oncotarget.23553
复制
发表时间：
2018-01-19
期刊：
影响因子：
--
通讯作者：
Danesi R
中科院分区：
文献类型：
--
作者：
Del Re M;Rofi E;Restante G;Crucitta S;Arrigoni E;Fogli S;Di Maio M;Petrini I;Danesi R
KRAS是最常见的，同时也是最模糊的与人类癌症有关的癌基因。尽管20多年前在非小细胞肺癌（NSCLC）中发现了KRAS突变，但尚未获得旨在直接消除KRAS活性的选择性和特异性抑制剂。尽管如此，已经开发了许多治疗方法，可用于治疗KRAS突变且对标准化疗和靶向治疗均难治的NSCLC患者。本综述的重点将是提供与复杂的分子KRAS通路相关的网络的概述，强调研究NSCLC患者中KRAS突变的预测价值的临床前和临床研究。检索Medline数据库中以英文发表的文献，检索关键词KRAS、KRAS突变在非小细胞肺癌中的作用、KRAS和肿瘤发生、KRAS和TKI、KRAS和化疗、KRAS和单克隆抗体、KRAS和免疫疗法、KRAS和药物、KRAS和耐药性。
KRAS is the most common and, simultaneously, the most ambiguous oncogene implicated in human cancer. Despite KRAS mutations were identified in Non Small Cell Lung Cancers (NSCLCs) more than 20 years ago, selective and specific inhibitors aimed at directly abrogating KRAS activity are not yet available. Nevertheless, many therapeutic approaches have been developed potentially useful to treat NSCLC patients mutated for KRAS and refractory to both standard chemotherapy and targeted therapies. The focus of this review will be to provide an overview of the network related to the intricate molecular KRAS pathways, stressing on preclinical and clinical studies that investigate the predictive value of KRAS mutations in NSCLC patients. A bibliographic search of the Medline database was conducted for articles published in English, with the keywords KRAS, KRAS mutations in non-small cell lung cancer, KRAS and tumorigenesis, KRAS and TKIs, KRAS and chemotherapy, KRAS and monoclonal antibody, KRAS and immunotherapy, KRAS and drugs, KRAS and drug resistance.